ArticleThe Journal of rheumatology2016
Giant Cell Arteritis: Visual Loss Is Our Major Concern.
Article in The Journal of rheumatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Increased expression of Toll-like receptors and associated alarmins in temporal arteries of patients with giant cell arteritis.Molecular medicine (Cambridge, Mass.) · 2025Article
- Article
- Sixth cranial nerve palsy in giant cell arteritis: A systematic review.Archives of rheumatology · 2024Article
- Increased interest with the introduction of fast-track diagnostic pathway is associated with the regionally increased frequency of giant cell arteritis in Poland: a study based on POLVAS registry data.Frontiers in medicine · 2024Article
- Evolution of the Therapeutic Management of Giant Cell Arteritis: Analysis of Real-Life Practices over Two Timeframes (2014-2017 and 2018-2020).Journal of clinical medicine · 2023Article
- Giant Cell Arteritis: State of the Art in Diagnosis, Monitoring, and Treatment.Rambam Maimonides medical journal · 2023Review
- Giant-cell arteritis related strokes: scoping review of mechanisms and rethinking treatment strategy?Frontiers in neurology · 2023Article
- Rare Ischemic Complications of Giant Cell Arteritis: Case Series and Literature Review.The American journal of case reports · 2022Review
- Advances in the Treatment of Giant Cell Arteritis.Journal of clinical medicine · 2022Review
- Novel aspects of regulatory T cell dysfunction as a therapeutic target in giant cell arteritis.Annals of the rheumatic diseases · 2022Article
- Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients.Therapeutic advances in musculoskeletal disease · 2022Article
- Imaging Tests in the Early Diagnosis of Giant Cell Arteritis.Journal of clinical medicine · 2021Review
- Vision loss in patients with giant cell arteritis treated with tocilizumab.Arthritis research & therapy · 2021Observational
- Biologic Therapies for Giant Cell Arteritis.Biologics : targets & therapy · 2021Review
- A Review of the Dermatological Complications of Giant Cell Arteritis.Clinical, cosmetic and investigational dermatology · 2021Review
- Giant cell arteritis: is the clinical spectrum of the disease changing?BMC geriatrics · 2019Review
- Visual loss in giant cell arteritis 3 weeks after steroid initiation.BMJ case reports · 2019Article
- Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data.Rheumatology and therapy · 2019Article
- Risk Associated with Cumulative Oral Glucocorticoid Use in Patients with Giant Cell Arteritis in Real-World Databases from the USA and UK.Rheumatology and therapy · 2018Article
- Profile of tocilizumab and its potential in the treatment of giant cell arteritis.Eye and brain · 2018Review
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
27481989What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.